Zoetis Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Comparisons are with the corresponding 2021 periods. Zoetis is a global animal-health company operating through U.S. and International segments.
Financial performance
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Revenue | $2.052B (+5%) | $1.948B | $4.038B (+6%) | $3.819B |
| Net income attributable to Zoetis | $529M (+3%) | $512M | $1.124B (+5%) | $1.071B |
| Diluted EPS | $1.12 | $1.07 | $2.38 | $2.24 |
| Adjusted net income (non-GAAP) | $567M (flat) | $566M | $1.192B (+2%) | $1.169B |
| Adjusted diluted EPS (non-GAAP) | $1.20 (+1%) | $1.19 | $2.52 (+3%) | $2.45 |
Growth and margins: Excluding foreign exchange, revenue grew 8% in Q2 and 9% in the first half; currency reduced reported growth by about 3 percentage points in each period. Q2 cost of sales rose 10% against 5% revenue growth, increasing cost of sales to 30.5% of revenue from 29.2%. First-half cost of sales was 29.6% versus 29.2%. U.S. segment gross margin was 81.9% in Q2 versus 80.9%; International margin was 69.5% versus 69.9%.
Cash flow and liquidity: First-half operating cash flow was $645M, down from $881M, primarily due to timing of receipts and payments and inventory build. Capital expenditures were $261M; investing cash outflow was $321M. Financing cash outflow was $1.155B, including $812M of share repurchases and $307M of dividends paid. Cash fell to $2.652B from $3.485B at year-end. Working capital declined to $3.600B from $5.133B, and the current ratio to 2.18 from 3.86.
Debt: At June 30, total debt was $6.650B principal, including $1.350B due in 2023 and classified as current; balance-sheet long-term debt, net, was $5.221B. The $1.0B revolving credit facility was undrawn, and Zoetis reported compliance with its debt covenants. Interest expense declined 7% year over year in both Q2 and the first half.
Material changes and business drivers
- Companion-animal revenue was a key growth driver: up 11% in Q2 and 14% in the first half. Growth included parasiticides, dermatology, and newer osteoarthritis products Librela and Solensia.
- Livestock revenue declined 4% in Q2 and 7% in the first half. U.S. cattle sales faced generic competition and difficult beef and dairy conditions; poultry sales were pressured by lower-cost alternatives and generic competition. International swine sales were affected by lower pork prices and China COVID-related disruptions.
- Operating expenses increased: Q2 SG&A rose 7% and R&D 13%; first-half SG&A rose 10% and R&D 8%. Management cited growth investments, compensation, travel, technology, freight/logistics, and R&D project spending.
- First-half reported net income grew 5%, while adjusted net income grew 2%. Lower restructuring and significant-item charges versus 2021 helped the reported comparison; higher operating costs and foreign-exchange effects remained pressures.
Outlook, risks, and unusual items
- The supplied filing text refers to 2022 financial guidance but does not provide clear numerical guidance values. Management said it expects available cash, operating cash flow, and financing arrangements to meet needs for the next twelve months and beyond, while noting economic conditions could affect liquidity.
- Management reported isolated supply-chain challenges expected to continue through the remainder of 2022. Inventory increased to support demand, launches, and supply availability.
- Russia’s invasion of Ukraine, sanctions, inflation, COVID-19, foreign exchange, generic competition, animal disease outbreaks, weather, and customer demand were identified as uncertainties. Zoetis expected sales in affected regions to be impacted but did not expect a material adverse effect on results or financial condition.
- Restructuring and acquisition-related costs were $1M in Q2 and $3M for the first half, compared with $21M and $30M in 2021. Basepaws was acquired in Q2 without significant financial-statement impact. The proposed Jurox acquisition remained subject to customary closing and regulatory conditions; the company expected completion in 2022.
- Legal matters include product-related claims and environmental proceedings. Management said it did not believe the matters would materially affect financial position, but could not estimate reasonably possible losses above amounts accrued. Tax authorities’ uncertain tax positions totaled $188M, excluding related interest and penalties.
- The 2018 $2.0B repurchase authorization was completed; approximately $3.4B remained under the $3.5B authorization approved in December 2021. First-half repurchases were 4.5 million shares for $812M.
Key facts for investors to verify
- Review the company’s complete 2022 guidance and any subsequent revisions; numerical guidance is not clear in the supplied filing text.
- Track whether inventory growth converts to sales and cash, given the first-half operating-cash-flow decline and working-capital reduction.
- Assess whether higher freight, manufacturing, and other costs continue to pressure margins despite pricing and product mix.
- Monitor 2023 debt refinancing plans for the $1.35B notes maturity and the effects of interest rates and foreign exchange.
- Follow livestock competition and market conditions, China supply-chain disruption, Ukraine-related impacts, and the Jurox acquisition status.
- Review legal and tax contingency developments; the filing does not quantify a clear maximum reasonably possible loss for legal matters.